Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer

References

• MorrisSWNaeveCMathewPALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin’s lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)Oncogene19971418217521889174053
   PubMed Web of Science ®Google Scholar
• InamuraKTakeuchiKTogashiYEML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onsetMod Pathol200922450851519234440
   PubMed Web of Science ®Google Scholar
• WongDWLeungELSoKKThe EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRASCancer200911581723173319170230
   PubMed Web of Science ®Google Scholar
• GerberDEMinnaJDALK inhibition for non-small cell lung cancer: from discovery to therapy in record timeCancer Cell201018654855121156280
   PubMed Web of Science ®Google Scholar
• LeeJKParkHSKimDWComparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancerCancer2012118143579358622086654
   PubMed Web of Science ®Google Scholar
• ShawATYeapBYSolomonBJImpact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with Historical controlsJ Clin Oncol20112915_suppl7507
   Google Scholar
• FDANDA 202570 Accelerated ApprovalUS Food and Drug Administration2011 Available from: https://www.accessdata.fda.gov/drug-satfda_docs/appletter/2011/202570s000ltr.pdfAccessed November 16, 2017
   Google Scholar
• KatayamaRShawATKhanTMMechanisms of acquired crizotinib resistance in ALK-rearranged lung cancersSci Transl Med20124120120ra17
   PubMed Web of Science ®Google Scholar
• LiaoBCLinCCShihJYYangJCTreating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategyTher Adv Med Oncol20157527429026327925
   PubMed Web of Science ®Google Scholar
• FDANDA 205755 Approval LetterUS Food and Drug Administration2014 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/205755Orig1s000ltr.pdfAccessed December 22, 2017
   Google Scholar
• FDANDA 205755/S-09 Supplement Approval Fulfillment of Postmarketing RequirementUS Food and Drug Administration2017 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/205755Orig1s009ltr.pdfAccessed March 7, 2018
   Google Scholar
• CDERApproval Package for Application Number 208434Orig1s000Center for Drug Evaluation and Research2015 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208434Orig1s000Approv.pdfAccessed March 7, 2018
   Google Scholar
• EMAAlecensa (Alectinib) Authorization DetailsEuropean Medicines Agency2017 Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004164/human_med_002068.jsp&mid=WC0b01ac058001d124Accessed March 7, 2018
   Google Scholar
• FDANDA 208434/S-03 Supplement Approval Fulfillment of Postmarketing RequirementUS Food and Drug Administration2017 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/208434Orig1s003ltr.pdfAccessed March 7, 2018
   Google Scholar
• Brigatinib Prescribing Information (United States)Cambridge, MAARIAD Pharmaceuticals, Inc.42017 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208772lbl.pdfAccessed December 19, 2017
   Google Scholar
• TamuraTKiuraKSetoTThree-year follow-up of an alectinib phase I/II study in ALK-positive non-small-cell lung cancer: AF-001JPJ Clin Oncol201735141515152128296581
   PubMed Web of Science ®Google Scholar
• HidaTNokiharaHKondoMAlectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trialLancet201739010089293928501140
   PubMed Web of Science ®Google Scholar
• PetersSCamidgeDRShawATAlectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancerN Engl J Med2017377982983828586279
   PubMed Web of Science ®Google Scholar
• TakiguchiYHidaTNokiharaHUpdated efficacy and safety of the J-ALEX study comparing alectinib (ALC) with crizotinib (CRZ) in ALK-inhibitor naïve ALK fusion positive non-small cell lung cancer (ALK+ NSCLC)Paper presented at: Annual Meeting of the American Society of Clinical Oncology2017Chicago, IL
   Google Scholar
• TanDFelipEChowLQCeritinib as first-line therapy in patients with ALK-rearranged non-small cell lung cancer: ASCEND-1 subgroup analysis17th World Conference on Lung CancerVienna, Austria2016
   Google Scholar
• FelipEOrlovSParkKPhase 2 study of ceritinib in ALKi-naïve patients (PTS) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC): whole body responses in the overall Pt group and in PTS with baseline brain metastases (BM)Ann Oncol201627suppl_612080
   Google Scholar
• de CastroGTanDS-WCrinòLPL03.07: first-line ceritinib versus chemotherapy in patients with ALK-rearranged (ALK+) NSCLC: a randomized, phase 3 study (ASCEND-4)J Thorac Oncol2017121S7
   Web of Science ®Google Scholar
• SoriaJCTanDSWChiariRFirst-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 studyLancet20173891007291792928126333
   PubMed Web of Science ®Google Scholar
• CamidgeDRBangYJKwakELActivity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 studyLancet Oncol201213101011101922954507
   PubMed Web of Science ®Google Scholar
• KimDWAhnMJShiYResults of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC)J Clin Oncol201230Suppl Abstract 7533
   Google Scholar
• ShawATJannePABesseBCrizotinib vs chemotherapy in ALK + advanced non-small cell lung cancer (NSCLC): final survival results from PROFILE 1007J Clin Oncol20163415_suppl9066
   Web of Science ®Google Scholar
• CostaDBShawATOuSHClinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastasesJ Clin Oncol201533171881188825624436
   PubMed Web of Science ®Google Scholar
• NishioMKimDWWuYLCrizotinib versus chemotherapy in Asian patients with ALK-positive advanced non-small cell lung cancerCancer Res Treat201850369170028701030
   PubMed Web of Science ®Google Scholar
• LeiYYYangJJZhongWZClinical efficacy of crizotinib in Chinese patients with ALK-positive non-small-cell lung cancer with brain metastasesJ Thorac Dis2015771181118826380734
   PubMed Web of Science ®Google Scholar
• ShawATKimDWNakagawaKCrizotinib versus chemotherapy in advanced ALK-positive lung cancerN Engl J Med2013368252385239423724913
   PubMed Web of Science ®Google Scholar
• SolomonBJCappuzzoFFelipEIntracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: results from PROFILE 1014J Clin Oncol201634242858286527022118
   PubMed Web of Science ®Google Scholar
• SolomonBJMokTKimDWFirst-line crizotinib versus chemotherapy in ALK-positive lung cancerN Engl J Med2014371232167217725470694
   PubMed Web of Science ®Google Scholar
• ShawATYeapBYSolomonBJEffect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisLancet Oncol201112111004101221933749
   PubMed Web of Science ®Google Scholar
• KwakELBangYJCamidgeDRAnaplastic lymphoma kinase inhibition in non-small-cell lung cancerN Engl J Med2010363181693170320979469
   PubMed Web of Science ®Google Scholar
• IwamaEGotoYMurakamiHAlectinib for patients with ALK rearrangement-positive non-small cell lung cancer and a poor performance status (Lung Oncology Group in Kyushu 1401)J Thorac Oncol20171271161116628238961
   PubMed Web of Science ®Google Scholar
• GettingerSNBazhenovaLALangerCJActivity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trialLancet Oncol201617121683169627836716
   PubMed Web of Science ®Google Scholar
• KimDWMehraRTanDSWActivity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trialLancet Oncol201617445246326973324
   PubMed Web of Science ®Google Scholar
• FelipETanDS-WKimD-WWhole body and intracranial efficacy of ceritinib in ALK-inhibitor (ALKi)-naive patients (pts) with ALK-rearranged (ALK+) NSCLC and baseline (BL) brain metastases (BM): Results from ASCEND-1 and -3J Clin Oncol20163415_supple20520
   Web of Science ®Google Scholar
• TanDSAraújoAZhangJComparative efficacy of ceritinib and crizotinib as initial ALK-Targeted therapies in previously treated advanced NSCLC: an adjusted comparison with external controlsJ Thorac Oncol20161191550155727288979
   PubMed Web of Science ®Google Scholar
• NishioMMurakamiHHoriikeAPhase I study of ceritinib (LDK378) in Japanese patients with advanced, anaplastic lymphoma kinase-rearranged non-small-cell lung cancer or other tumorsJ Thorac Oncol20151071058106626020125
   PubMed Web of Science ®Google Scholar
• ShawATKimDWMehraRCeritinib in ALK-rearranged non-small-cell lung cancerN Engl J Med2014370131189119724670165
   PubMed Web of Science ®Google Scholar
• FelipEde BraudFGMaurMCeritinib plus nivolumab (NIVO) in patients (pts) with anaplastic lymphoma kinase positive (ALK+) advanced non-small cell lung cancer (NSCLC)Paper Presented at: Annual Meeting of the American Society of Clinical Oncology2017Chicago, IL
   Google Scholar
• MurakamiHOnoANakashimaKLong-term clinical outcomes of ALK inhibitors in patients with ALK-positive advanced non-small cell lung cancerJ Clin Oncol20173515_supple20542
   Web of Science ®Google Scholar
• ItoKHatajiOKobayashiHSequential therapy with crizotinib and alectinib in ALK-rearranged non-small cell lung cancer – a multi-center retrospective studyJ Thorac Oncol201712239039627498387
   PubMed Web of Science ®Google Scholar
• ChiariRMetroGIaconoDClinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: results of a multicenter analysisLung Cancer201590225526026395848
   PubMed Web of Science ®Google Scholar
• AsaoTFujiwaraYItahashiKSequential use of anaplastic lymphoma kinase inhibitors in Japanese patients with ALK-rearranged non-small-cell lung cancer: a retrospective analysisClin Lung Cancer2017184e251e25828065466
   PubMed Web of Science ®Google Scholar
• NosakiKToyozawaRTaguchiKReal-world data on treatment patterns and survival among ALK+ NSCLC patients in JapanJ Clin Oncol20173515_supple20505
   Web of Science ®Google Scholar
• KayaniyilSHurryMWilsonJTreatment patterns and survival in patients with ALK-positive non-small-cell lung cancer: a Canadian retrospective studyCurr Oncol2016236589e597
   Web of Science ®Google Scholar
• BergeEMLuXMaxsonDClinical benefit from pemetrexed before and after crizotinib exposure and from crizotinib before and after pemetrexed exposure in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancerClin Lung Cancer201314663664323931899
   PubMed Web of Science ®Google Scholar
• CadranelJParkKArrietaOCharacteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: a chart review studyLung Cancer20169891427393500
   PubMed Web of Science ®Google Scholar
• CaoYXiaoGQiuXYeSLinTEfficacy and safety of crizotinib among Chinese EML4-ALK-positive, advanced-stage non-small cell lung cancer patientsPLoS One2014912e11400825501361
   PubMed Web of Science ®Google Scholar
• CuiSZhaoYDongLIs there a progression-free survival benefit of first-line crizotinib versus standard chemotherapy and second-line crizotinib in ALK-positive advanced lung adenocarcinoma? A retrospective study of Chinese patientsCancer Med2016561013102126880708
   PubMed Web of Science ®Google Scholar
• CuiSZhaoYGuAEfficacy and tolerability of crizotinib in the treatment of ALK-positive, advanced non-small cell lung cancer in Chinese patientsMed Oncol201532662625966792
   PubMed Web of Science ®Google Scholar
• DuruisseauxMBesseBCadranelJOverall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective studyOncotarget2017813219032191728423535
   PubMedGoogle Scholar
• LimSHYohKALeeJSCharacteristics and outcomes of ALK+ non-small cell lung cancer patients in KoreaAsia Pac J Clin Oncol2017
   Web of Science ®Google Scholar
• NoronhaVRamaswamyAPatilVMALK positive lung cancer: clinical profile, practice and outcomes in a developing countryPLoS One2016119e016075227637025
   PubMed Web of Science ®Google Scholar
• YoshidaTOyaYTanakaKClinical impact of crizotinib on central nervous system progression in ALK-positive non-small lung cancerLung Cancer201697434727237026
   PubMed Web of Science ®Google Scholar
• XingPWangSHaoXZhangTLiJClinical data from the real world: efficacy of crizotinib in Chinese patients with advanced ALK-rearranged non-small cell lung cancer and brain metastasesOncotarget2016751846668467427835868
   PubMedGoogle Scholar
• ZhangQQinNWangJCrizotinib versus platinum-based double-agent chemotherapy as the first line treatment in advanced anaplastic lymphoma kinase-positive lung adenocarcinomaThorac Cancer2016713826816533
   PubMed Web of Science ®Google Scholar
• GuérinASasaneMWakeleeHTreatment, overall survival, and costs in patients with ALK-positive non-small-cell lung cancer after crizotinib monotherapyCurr Med Res Opin20153181587159726029864
   PubMed Web of Science ®Google Scholar
• BarlesiFDingemansA-MCYangJC-HUpdated efficacy and safety from the global phase II NP28673 study of alectinib in patients (PTS) with previously treated ALK+ non-small-cell lung cancer (NSCLC)Ann Oncol201627suppl_6
   Google Scholar
• OuSHAhnJSde PetrisLAlectinib in Crizotinib-Refractory ALK-rearranged non-small-cell lung cancer: a phase II global studyJ Clin Oncol201634766166826598747
   PubMed Web of Science ®Google Scholar
• ShawATGandhiLGadgeelSAlectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multi-centre, phase 2 trialLancet Oncol201617223424226708155
   PubMed Web of Science ®Google Scholar
• CamidgeDRSmGOuSUpdated efficacy and safety data from the phase 2 NP28761 study of alectinib in ALK-positive non-small-cell lung cancer (now available)17th World Conference on Lung CancerVienna, Austria2016
   Google Scholar
• YangJCSiOde PetrisLPooled systemic efficacy and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancerJ Thorac Oncol2017
   Google Scholar
• GandhiLOuSIShawATEfficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: comparison of RECIST 1.1 and RANO-HGG criteriaEur J Cancer201782273328646771
   PubMed Web of Science ®Google Scholar
• GandhiLGadgeelSShawATime to response in patients with ALK+ NSCLC receiving alectinib in the phase II NP28673 and NP28761 studiesAnn Oncol201627suppl_61209PD
   Google Scholar
• GadgeelSMShawATGovindanRPooled analysis of CNS response to alectinib in two studies of pretreated patients with ALK-positive non-small-cell lung cancerJ Clin Oncol201634344079408527863201
   PubMed Web of Science ®Google Scholar
• GadgeelSMGandhiLRielyGJSafety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 studyLancet Oncol201415101119112825153538
   PubMed Web of Science ®Google Scholar
• AhnM-JCamidgeDRTiseoMBrigatinib (BRG) in crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): updates from ALTA, a pivotal randomized phase 2 trialPaper presented at: Annual Meeting of the American Society of Clinical Oncology;2017Chicago, IL
   Google Scholar
• CamidgeDRBazhenovaLASalgiaRAssessment of brigatinib (AP26113) CNS activity in patients (Pts) with ALK+ NSCLC and intracranial metastases in a phase 1/2 study18th European Cancer CongressVienna, Austria2015
   Google Scholar
• GettingerSNKimDTiseoMBrigatinib activity in patients with ALK+ NSCLC and intracranial CNS metastases in two clinical trials17th World Conference on Lung CancerVienna, Austria2016
   Google Scholar
• KimD-WTiseoMAhnM-JBrigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trialJ Clin Oncol201735222490249828475456
   PubMed Web of Science ®Google Scholar
• OuSHTiseoMCamidgeDRBrigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC) and brain metastases in the pivotal randomized phase 2 ALTA trialPaper presented at: Annual Meeting of the American Society of Clinical Oncology2017Chicago, IL
   Google Scholar
• CrinòLAhnMJde MarinisFMulticenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: results from ASCEND-2J Clin Oncol201634242866287327432917
   PubMed Web of Science ®Google Scholar
• HidaTSatouchiMNakagawaKCeritinib in patients with advanced, crizotinib-treated, anaplastic lymphoma kinase-rearranged NSCLC: Japanese subsetJpn J Clin Oncol20171727989996
   PubMed Web of Science ®Google Scholar
• ShawATKimTMCrinòLCeritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trialLancet Oncol201718787488628602779
   PubMed Web of Science ®Google Scholar
• HidaTNakagawaKSetoTPharmacologic study (JP28927) of alectinib in Japanese patients with ALK+ non-small-cell lung cancer with or without prior crizotinib therapyCancer Sci2016107111642164627566263
   PubMed Web of Science ®Google Scholar
• LiuGZhangJZhouZYLiJCaiXSignorovitchJAssociation between time to progression and subsequent survival in ceritinib-treated patients with advanced ALK-positive non-small-cell lung cancerCurr Med Res Opin201632111911191827488695
   PubMed Web of Science ®Google Scholar
• BendalyEDalalAACulverKTreatment patterns and early outcomes of ALK-positive non-small cell lung cancer patients receiving ceritinib: a chart review studyAdv Ther20173451145115628405961
   PubMed Web of Science ®Google Scholar
• BendalyEDalalAACulverKMonitoring for and characterizing crizotinib progression: a chart review of ALK-positive non-small cell lung cancer patientsAdv Ther20173471673168528578501
   PubMed Web of Science ®Google Scholar
• GainorJFTanDSde PasTProgression-free and overall survival in ALK-positive NSCLC patients treated with sequential crizotinib and ceritinibClin Cancer Res201521122745275225724526
   PubMed Web of Science ®Google Scholar
• RoeperJNetchaevaMLueersACImpact on OS of 2nd and 3rd generation TKI in EGFR mt+ and ALK+ patients: Results of the NOWEL networkJ Clin Oncol20173515_supple20560
   Web of Science ®Google Scholar
• WatanabeSHayashiHOkamotoKProgression-free and overall survival of patients with ALK rearrangement-positive non-small cell lung cancer treated sequentially with crizotinib and alectinibClin Lung Cancer201617652853427318655
   PubMed Web of Science ®Google Scholar
• LORBRENA (lorlatinib)U.S. Prescribing InformationNew York, NYPfizer Inc2018
   Google Scholar
• SolomonBJBesseBBauerTMLorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 studyLancet Oncol201819121654166730413378
   PubMed Web of Science ®Google Scholar
• MokTSKKimD-WWuY-LOverall survival (OS) for first-line crizotinib versus chemotherapy in ALK+ lung cancer: updated results from PROFILE 1014Paper presented at: Annual Meeting of the European Society for Medical Oncology2017Madrid, Spain
   Google Scholar